Company profile: Cognito Therapeutics
1.1 - Company Overview
Company description
- Provider of non-invasive gamma wave therapy that evokes brain gamma activity via visual and auditory stimulation to slow cognitive and functional decline in Alzheimer’s; personalized intensity guided by EEG. Runs the HOPE pivotal study and Phase 2 OVERTURE showing preserved cognition, daily function, and brain volume. Holds FDA Breakthrough Device Designation; developing disease-modifying treatments for CNS illnesses.
Products and services
- Non-invasive Gamma Wave Therapy: FDA Breakthrough Device–designated treatment that evokes gamma wave activity via visual and auditory stimulation to slow cognitive and functional decline, with intensity tailored by EEG evaluation
- HOPE Study: Randomized trial investigating the safety and efficacy of the company's treatment in mild-to-moderate Alzheimer’s Disease
- Phase 2 OVERTURE Study: Phase 2 clinical study that demonstrated the therapy slowed disease progression by preserving cognition, daily function, and brain volume in Alzheimer’s patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cognito Therapeutics
Synaptive Medical
HQ: Canada
Website
- Description: Provider of neurosurgery, medical imaging and surgical navigation solutions, including the Synaptive Integrated Suite to integrate information and automation across interventions; Modus X robotic exoscope with 4K 3D and fluorescence visualization; Modus Plan automatic tractography segmentation; Modus Nav instrument tracking via intraoperative tractography; Synaptive MRI point-of-care MRI; ImageDrive zero-footprint HTML5 viewer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptive Medical company profile →
Catalyst Pharmaceuticals
HQ: United States
Website
- Description: Provider of prescription drug development and commercialization, offering FIRDAPSE (FDA-approved for adults with Lambert-Eaton myasthenic syndrome) and FYCOMPA (for partial-onset seizures in individuals 4+ and primary generalized tonic-clonic seizures in those 12+). Supports investigator-sponsored research in LEMS and hereditary neuropathy and provides a U.S. expanded access program offering its lead product at no charge prior to FDA approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Catalyst Pharmaceuticals company profile →
Trophos
HQ: France
Website
- Description: Provider of clinical-stage pharmaceutical R&D developing innovative therapeutics for under-served needs in neurology and cardiology, with a pipeline of original molecules targeting motoneuron diseases such as amyotrophic lateral sclerosis (ALS).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trophos company profile →
Rapid Dose Therapeutics
HQ: Canada
Website
- Description: Provider of pharma-tech oral fast-dissolving drug delivery solutions, including QuickStrip for direct bloodstream delivery of pharmaceuticals and over-the-counter medicines; RDMx + QuickStrip for enabling delivery of large therapeutic molecules; Rapid Energy, Vitamin B12, and Melatonin QuickStrip products; and versions for elderly and pediatric patients needing simplified, rapid dosing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rapid Dose Therapeutics company profile →
Scienture
HQ: United States
Website
- Description: Provider of pharmaceutical research focused on drug screening, with a pipeline including SCN-102 (oral cardiovascular liquid; FDA-accepted NDA), SCN-104 (self-injectable CNS/pain drug-device; advanced development), SCN-107 (long-acting pain injection; formulation optimization with pre-clinical planned), and SCN-106 (early-stage biosimilar; clone selection completed; BIA meeting planned).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scienture company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cognito Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cognito Therapeutics
2.2 - Growth funds investing in similar companies to Cognito Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cognito Therapeutics
4.2 - Public trading comparable groups for Cognito Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →